US Edition
US court blocks mail-order access to abortion drugs, for now
The ruling could curb telehealth abortion access nationwide, and judges said the policy likely leads to nearly 1,000 illegal abortions a month in Louisiana.
- On Friday, May 1, 2026, the 5th U.S. Circuit Court of Appeals issued a temporary stay blocking the Food and Drug Administration's 2023 policy permitting mail-order mifepristone, reinstating nationwide in-person dispensing requirements while Louisiana's legal challenge proceeds.
- Louisiana Attorney General Liz Murrill sued the FDA, arguing the 2023 rule undermined state abortion bans and caused the state $92,000 in Medicaid costs for emergency care from out-of-state mifepristone complications.
- Circuit Judge Stuart Kyle Duncan wrote that the policy "facilitates nearly 1,000 illegal abortions in Louisiana per month," while the panel ruled federal regulations created an end-run around the state's prohibition where medication now accounts for two-thirds of U.S. abortions.
- Julia Kaye, an American Civil Liberties Union lawyer, warned the ruling will "affect patients' access to abortion and miscarriage care in every state," while Susan B. Anthony Pro-Life America celebrated it as a "huge victory" against the "mail-order abortion drug regime."
- Legal experts anticipate a likely appeal to the Supreme Court, while providers prepare contingency plans including efforts to offer alternative misoprostol-only regimens to patients who can no longer access mifepristone via telehealth.
326 Articles
326 Articles
Prescribing medications such as Mifepriston with subsequent delivery by post is one of the most important ways of abortion in the United States. Now, a court in Louisiana puts a bar on the method.
An American court of appeal temporarily suspended the possibility of sending the mifepristone by post on Friday, May 1. Used in the majority of abortions, this medicine has become an essential lever to circumvent local prohibitions since the decision of the Supreme Court of the United States in 2022.
US Appeals Court Ruling Targets Access to Abortion Medication
Rights advocates swiftly sounded the alarm on Friday after the infamously far-right U.S. Court of Appeals for the 5th Circuit temporarily blocked a federal rule allowing mifepristone to be dispensed by mail, dramatically curtailing access to the medication — commonly used for abortion and early miscarriage care — nationwide, particularly in states with policies hostile to reproductive freedom. Source
Abortion Pills Can No Longer Be Sent by Mail as US Court Ruling Reinforces In-Person Pick-Up Only
A US federal appeals court has ruled that abortion pills, specifically mifepristone, can no longer be prescribed through telehealth or sent by mail, according to a decision from the 5th US Circuit Court of Appeals in Louisiana on Friday. The ruling on abortion pills sent by mail effectively restores an earlier requirement that patients must collect the medication in person from a healthcare provider. The news came after years of shifting federal…
Court ruling fuels new push to restrict abortion pills by mail
The fight over abortion pills isn’t happening in a courtroom alone — it’s landing in Americans’ mailboxes. For many patients, birth control and other reproductive health medications already arrive by delivery, prescribed through telehealth and filled by out-of-state pharmacies. But as conservative states move to restrict access to abortion pills like mifepristone, that everyday convenience is colliding with a new and complicated legal reality. A…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
